NCT06098898 2023-10-25
Safety and Efficacy of NK510 to Treat Gastric Cancer
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1 Unknown
Clinical Trials
9 trialsNCT04819971 2023-04-25
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04888663 2021-05-21
Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)
Yonsei University
Phase 1/2 Unknown
NCT02901301 2021-04-06
Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer
Yonsei University
Phase 1/2 Unknown
NCT01359397 2021-01-27
B-DOCT
The Netherlands Cancer Institute
Phase 2 Unknown
NCT01228045 2016-06-22
A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
National University Hospital, Singapore
Phase 2 Unknown
NCT02030561 2016-06-22
NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer
National University Hospital, Singapore
Phase 1/2 Unknown
NCT02805829 2016-06-22
Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer
Xuzhou Medical University
Phase 1/2 Unknown
NCT02250209 2014-09-26
T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy
Chinese PLA General Hospital
Phase 2 Unknown